Pharmaxis On Investors' Radar

Since July of last year both Credit Suisse and RBS Australia have rated Australian pharmaceutical company Pharmaxis (PXS) as a Buy. BA Merrill Lynch has now added to the positive views on the stock, initiating coverage today with a Buy rating and a price target of $3.55.

Read More

Analyst Views